This study suggests that obesity is associated with an increased risk of recurrence among patients with hormone receptor–positive breast cancer treated with aromatase inhibitors, highlighting the need for optimization of care in patients with breast cancer and obesity. This evidence concerns the gene NR4A1 and breast carcinoma.